YCG
ALNY icon

Yeomans Consulting Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Yeomans Consulting Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-984
Closed -$453K – 114
2025
Q3 		$453K Buy
+984
New +$401K 0.16% 64

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Yeomans Consulting Group's ALNY Position: Q4 2025 in Review

Yeomans Consulting Group sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 984 shares — an estimated $453K sold.

Yeomans Consulting Group first reported a position in ALNY in Q3 2025 and held it in 1 quarter. The position peaked at $453K in Q3 2025. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • Yeomans Consulting Group reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Yeomans Consulting Group sold 984 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $453K.
  • Yeomans Consulting Group first reported a position in Alnylam Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Yeomans Consulting Group's Alnylam Pharmaceuticals position peaked at $453K in Q3 2025.
  • 851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Yeomans Consulting Group's 13F filing for Q4 2025, filed 7 Jan 2026.